A comprehensive review in Frontiers in Pharmacology demonstrates that the transition of infantile hemangioma from rapid postnatal proliferation to spontaneous involution involves cellular reprogramming, immune shifts, and programmed cell death operating through localized circuits rather than a rigid, sequential causal cascade. Infantile hemangioma represents the most common benign vascular tumor of infancy, defined by a unique life cycle where excessive vascular proliferation gives way to slow regression and fibrofatty replacement. Researchers led by Haoyi Liang evaluated the multidimensional biology driving this stage transition, synthesizing evidence across hemangioma endothelial cells, multipotent stem cells, and infiltrating immune populations. While earlier investigations focused predominantly on isolated angiogenic signaling molecules, this analysis highlights that the shift between growth and regression cannot be reduced to a single continuous regulatory chain. Instead, distinct cellular compartments undergo autonomous metabolic alterations and microenvironmental adaptations, explaining why treatment responses vary and providing a structured framework for investigating spontaneous tumor involution.
Clinically, infantile hemangioma affects four to ten percent of live-born infants, with established risk factors including low birth weight, prematurity, female sex, multiple gestation, and family history. Epidemiological data indicate a higher incidence among Caucasian infants compared to Asian and African populations, with females affected three to four times more often than males. Lesions typically appear within days or weeks following birth, proliferate rapidly between three and five months of age, and complete expansion before nine months before entering an involution phase lasting several years. Unlike congenital vascular malformations present at birth, infantile hemangioma stains positive for glucose transporter 1, distinguishing it from static vascular anomalies. Lesions are classified as superficial, deep, or mixed, occurring most frequently on the trunk and head. Although benign, hemangiomas can cause permanent cutaneous scarring, disfigurement, or functional impairment when obstructing airways, eyes, or lips, with ulceration arising as a complication in approximately 15.8 percent of clinical cases.
At the cellular level, infantile hemangioma arises from multipotent hemangioma stem cells capable of clonogenic expansion and multilineage differentiation. During the rapid proliferative phase, local hypoxia serves as a critical upstream initiating stimulus, activating hypoxia-inducible factors and elevating vascular endothelial growth factor levels that peak during active growth and decline during involution. This hypoxic drive sustains an autocrine signaling loop involving vascular endothelial growth factor receptor 2, which activates downstream intracellular pathways including PI3K, AKT, and MAPK or ERK to promote endothelial proliferation and vessel sprouting. Concurrently, hemangioma stem cells differentiate into hemangioma endothelial cells and pericytes, with endothelial Jagged1 directing pericyte recruitment via Notch signaling to assemble disorganized vascular networks. Additional pathways, including the renin-angiotensin system, beta-adrenergic signaling, and the transcription factor SOX18-mevalonate axis, further promote abnormal angiogenesis. In general vascular models, Notch ligands like DLL4 govern arterial specification, although confirmation of equivalent arteriolar programming in hemangioma tissue requires further study.
Proliferating hemangioma endothelial cells exhibit marked glycolytic reprogramming, elevating glucose consumption, hexokinase 2 expression, and adenosine triphosphate production to fuel rapid vessel sprouting. The review details how signaling through the PI3K, AKT, and mTOR axis stabilizes hypoxia-inducible factor 1-alpha, driving the transcriptional activation of key glycolytic components including hexokinase 2, PFKFB3, and glucose transporter 1. Noncoding regulatory networks reinforce this metabolic state; the long noncoding RNA MCM3AP-AS1 promotes hypoxia-inducible factor 1-alpha expression through competing endogenous RNA mechanisms, while the m6A reader YTHDF1 binds and stabilizes glucose transporter 1 transcripts. Furthermore, the deubiquitinase OTUB1 stabilizes transforming growth factor beta-induced protein to amplify downstream glycolytic signaling, and the epigenetic HECW2-ALKBH5 axis regulates lactate dehydrogenase A to accelerate pyruvate conversion into lactate. Pharmacological inhibition using agents like 3-bromopyruvate or PFK15 curbs endothelial proliferation, demonstrating that targeted disruption of glycolytic reprogramming can suppress pathological hemangioma vascular expansion.
Beyond glucose metabolism, metabolomic analyses reveal extensive alterations in amino acid pathways within infantile hemangioma. Hemangioma endothelial cells display significant differences across sixteen amino acid metabolites when compared to human umbilical vein endothelial cells, showing prominent remodeling in glutamate, arginine, and glycine or serine metabolism. Correspondingly, metabolomic screening of umbilical cord blood from infants who subsequently developed hemangiomas identified early alterations in alanine, aspartate, and glutamate metabolism, alongside arginine biosynthesis. Evidence from general vascular biology indicates that glutamine catabolism via glutaminase 1 supplies essential carbon intermediates to the tricarboxylic acid cycle, while GlyT1-dependent glycine transport and MTHFD2-driven one-carbon metabolism sustain endothelial proliferation. Furthermore, the expression of indoleamine 2,3-dioxygenase in proliferating hemangiomas links tryptophan degradation to local immune regulation. However, the authors caution that existing hemangioma data reflect steady-state metabolite measurements rather than dynamic metabolic fluxes, emphasizing that while amino acid networks represent promising metabolic nodes, their specific longitudinal roles during hemangioma regression await formal validation.
During the involuting phase, the dense vascular architecture of the lesion regresses and is systematically replaced by fibrofatty tissue, a histological transformation driven by cell-fate transitions. Rather than representing an intrinsic lipid metabolic shift within existing endothelial cells, this tissue remodeling reflects the commitment of hemangioma stem cells toward an adipogenic lineage. Signaling investigations show that insulin-like growth factor 1 promotes adipogenic differentiation through the IGF-1R, PI3K, and AKT pathways, which upregulate adipogenic transcription factors including PPAR-gamma and members of the C/EBP family. Conversely, the transcription factor KLF2 acts as an essential molecular regulator: high KLF2 expression maintains endothelial commitment while its downregulation permits adipogenic differentiation. First-line therapy with propranolol promotes stem cell adipogenesis, accompanied by increased phosphorylated AKT and PPAR-gamma levels, while concurrently suppressing endothelial glycolysis. The authors emphasize that this structural replacement signifies a profound remodeling of lesional cellular composition rather than a mere continuation of metabolic reprogramming within a single static cell population.
Stage-dependent remodeling of the lesional immune microenvironment also dictates vascular expansion and subsequent regression. During the proliferative phase, infiltrating M2-like macrophages establish a proangiogenic niche, transferring exosomal lncRNA MIR4435-2HG to endothelial cells to activate NF-kappa-B signaling, while directing hemangioma stem cells away from adipogenesis via AKT and ERK pathways. Concurrently, resident mast cells display elevated estrogen receptor-alpha expression and release proangiogenic mediators such as AGGF1, basic fibroblast growth factor, and VEGF. Adaptive immune profiling reveals decreased infiltration of CD8-positive T cells and Th17 cells alongside enriched gamma-delta T cells during active proliferation. As involution proceeds, this microenvironment shifts markedly: M1-like macrophages secrete tumor necrosis factor-alpha, which triggers endothelial-to-mesenchymal transition in hemangioma endothelial cells to dissolve vascular structures. Furthermore, mast cells increase in abundance, secreting antiangiogenic factors such as interferons and transforming growth factor-beta, while the adaptive compartment shows increased CD8-positive and Th17 cells, reflecting an organized transition toward vascular regression.
Programmed cell death forms another central biological pillar governing the balance between hemangioma proliferation and regression, with apoptosis presenting the most robust experimental evidence. During spontaneous involution, the tumor suppressor p53 is markedly upregulated within endothelial cells, where it transcriptionally activates proapoptotic BAX and suppresses VEGF expression, simultaneously dismantling survival signaling through the AKT and ERK cascades. The subsequent loss of mitochondrial membrane integrity prompts cytochrome c release and caspase-3 activation, culminating in orderly cellular disassembly. Specific microRNAs, including miR-4458 and miR-199a-5p, further sensitize endothelial cells to apoptosis by targeting IGF-1R and hypoxia-inducible factor 1-alpha, respectively. Pharmacologically, propranolol accelerates this intrinsic apoptotic program by enhancing p53 and BAX transcription, downregulating the survival factor IGFBP3, and facilitating caspase cleavage. Although related in vitro studies utilizing human umbilical vein endothelial cells demonstrated that propranolol elevates apoptotic protease-activating factor 1 to amplify death signaling, direct verification of this specific amplification step within patient-derived hemangioma endothelial tissue remains necessary.
In contrast to apoptosis, non-apoptotic modes of regulated cell death—including pyroptosis, necroptosis, ferroptosis, and autophagy—display variable and largely correlative supporting evidence in hemangioma pathology. Bioinformatic screens have identified differentially expressed gene clusters linked to pyroptosis, such as IL6, EGFR, IRF1, and IL32, alongside necroptosis-related markers including CHMP4B and EPAS1, yet functional activation of canonical execution pathways remains unverified in spontaneous regression. Studies examining ferroptosis reveal that hemangioma stem cells protect macrophages from iron-dependent death via the Nrf2-GPX4 axis during proliferation, while elevated levels of the lipid peroxidation marker 4-HNE appear during involution. Autophagy-lysosome markers, specifically lysosome-associated membrane proteins, increase during regression, but elevated staining does not establish lethal autophagic flux. Crucially, the review addresses PANoptosis, an integrated concept where pyroptotic, apoptotic, and necroptotic machinery assemble into a single PANoptosome complex. The authors clarify that PANoptosis currently remains an unverified hypothesis in infantile hemangioma, lacking biochemical proof of complex assembly or simultaneous multilinear pathway activation within identical tumor cells.
Translating these multidimensional mechanisms into improved clinical management addresses real-world challenges, including variable patient sensitivity, refractory lesions, and rebound growth following propranolol discontinuation. While propranolol remains the standard first-line targeted therapy, its efficacy is modulated by underlying metabolic resistance; hyperactive glycolysis mediated by the YTHDF1-GLUT1 axis reduces drug responsiveness, whereas experimental inhibition of pyruvate kinase M2 by shikonin restores therapeutic sensitivity. Other experimental strategies, such as engineered iron-releasing nanoparticles that induce lethal ferroptosis via local Fenton reactions, demonstrate potential for clearing refractory endothelial cells. However, the authors caution that clinical evidence currently does not support indiscriminately combining metabolic, immune, and cell-death therapies. Instead, future efforts must focus on defining the upstream triggers that initiate natural involution, separating intrinsic cell reprogramming from tissue-averaged composition shifts, and mapping longitudinal metabolic fluxes. By establishing validated biomarkers to stratify patients with resistant disease, researchers can develop precisely timed, cell-specific interventions that mirror the natural biological resolution of infantile hemangioma.
Subject of Research: Pathological mechanisms governing proliferation and involution in infantile hemangioma
Article Title: Multidimensional analysis of the pathological mechanisms of infantile hemangioma: metabolic reprogramming, immune remodeling, and programmed cell death
Article References: Liang, H., Pan, H., An, Y., Chen, Y., Li, W., Wei, Z., Liu, C., Zhu, H., & Hu, H. (2026). Multidimensional analysis of the pathological mechanisms of infantile hemangioma: metabolic reprogramming, immune remodeling, and programmed cell death. Frontiers in Pharmacology, 17, Article 1971229. https://doi.org/10.3389/fphar.2026.1971229
Image Credits: AI Generated
DOI: 10.3389/fphar.2026.1971229
Keywords: infantile hemangioma, hemangioma endothelial cells, hemangioma stem cells, metabolic reprogramming, glycolysis, immune microenvironment, macrophages, mast cells, programmed cell death, apoptosis, pyroptosis, necroptosis, ferroptosis, PANoptosis, propranolol, adipogenic differentiation, angiogenesis, GLUT1
News Source: Ophelia Keating. (November 17, 2026). Infantile Hemangioma Regression Involves Local Cellular Circuits Rather Than Sequential Cascades. Scienmag.



